(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 January 2023 (19.01.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/288241 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2022/073671

(22) International Filing Date:
13 July 2022 (13.07.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/221,734 14 July 2021 (14.07.2021) US
63/253,676 08 October 2021 (08.10.2021) US

(71) Applicant: **GENENTECH, INC.** [US/US]; 1 Dna Way, South San Francisco, CA 94080-4990 (US).

(72) Inventors: **GAMPA, Gautham**; C/o Genentech, Inc., 1 Dna Way, South San Francisco, CA 94080-4990 (US). **HOSSEINI, Iraj**; C/o Genentech, Inc., 1 Dna Way, South San Francisco, CA 94080-4990 (US). **HUSENI, Mahrukh**; C/o Genentech, Inc., 1 Dna Way, South San Francisco, CA 94080-4990 (US). **KOERBER, James, Thomas**; C/o Genentech, Inc., 1 Dna Way, South San Francisco, CA 94080-4990 (US). **PAYANDEH, Jian, Mehr-dean**; C/o Genentech, Inc., 1 Dna Way, South San Francisco, CA 94080-4990 (US). **RUTZ, Sascha**; C/o Genentech, Inc., 1 Dna Way, South San Francisco, CA 94080-4990 (US). **SUN, Yonglian**; C/o Genentech, Inc., 1 Dna Way, South San Francisco, CA 94080-4990 (US). **CHIU, Cecilia, Pui Chi**; C/o Genentech, Inc., 1 Dna Way, South San Francisco, CA 94080-4990 (US). **DELFINO, Teresita, Arenzana**; C/o Genentech, Inc., 1 Dna Way, South San Francisco, CA 94080-4990 (US).

(74) Agent: **TAKARA, Thomas J.** et al.; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: ANTI-C-C MOTIF CHEMOKINE RECEPTOR 8 (CCR8) ANTIBODIES AND METHODS OF USE




FIG. 1

(57) Abstract: The present disclosure provides anti-CCR8 antibodies, and compositions and methods of their preparation and use.

[Continued on next page]

WO 2023/288241 A1

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*